This information is for educational purposes only. Off-label drug use carries risks. Always consult a qualified physician before using any drug outside its approved indication.
Fenbendazole
Fenbendazole
Brand names: Panacur, Safe-Guard, Fenbend
ORIGINALLY APPROVED FOR
Veterinary Anthelmintic (pinworms, roundworms, hookworms, whipworms in animals)
Fenbendazole is a broad-spectrum veterinary anthelmintic in the same benzimidazole class as mebendazole, but with a different pharmacokinetic profile and formulation. It gained significant public attention following the widely shared story of Joe Tippens, an American cancer patient who reported complete remission of Stage 4 small cell lung cancer after taking fenbendazole alongside other supplements. While this is a single anecdotal case, it triggered a surge in preclinical research — primarily from South Korean labs — showing fenbendazole inhibits tubulin polymerisation, stabilises p53 tumour suppressor protein, blocks GLUT glucose transporters (starving cancer cells of sugar), and disrupts cancer cell metabolism. It is chemically closely related to mebendazole but is formulated for animals and has not been studied in formal human clinical trials.
Molecular Pathways Targeted
Mechanism of Action in Cancer
Binds beta-tubulin → prevents microtubule polymerisation → arrests mitosis (same mechanism as mebendazole and taxanes). Additionally: stabilises mutant p53 into wild-type-like conformation (restoring tumour suppressor function), blocks GLUT1/4 glucose transporters (metabolic starvation of cancer cells), and inhibits Akt/mTOR signalling. Multi-pathway disruption may explain preclinical potency.
Cancers Studied
Typical Off-Label Dosing
222 mg (1 packet of Panacur C granules) 3 days on, 4 days off per week. The Joe Tippens protocol includes vitamin E succinate, CBD oil, and curcumin alongside. Taken with food. No approved human dose — this is based entirely on self-reporting and preclinical extrapolation.
* Dosing information from research literature only. Not a prescription. Requires physician supervision.
Cautions & Drug Interactions
- Not approved for human use — formulated for animals with excipients not evaluated in humans
- All clinical evidence is anecdotal or preclinical only — no completed human trials
- Potential liver toxicity — monitor liver function tests regularly
- May interact with immunosuppressants and anticoagulants
- Bioavailability in humans is poorly characterised
- Do not discontinue conventional cancer treatment based on anecdotal reports
- Joe Tippens also received immunotherapy (pembrolizumab) — the role of fenbendazole vs. immunotherapy in his response is unknown